Member Info for Steadydanny

The posts get removed!! ! !!!

Ndr this from Sierra Oncology
SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022.
Today's the 12th. 9 times out of 10 we update an SO update.

Let's see what happens. I pointed out that 737 was getting more updates before. And we did. Let's see.
So do I do lemon and sugar or golden syrup pancakes?
Recipes and additions to the world of pancakes appreciated.
They are flat. We ain't!

Respect this is a discussion board. I've only recently via research and company link ups realised that some of the lths are quiet. Sell if you want. Research back to 2017 if you want. That's why some posters say imo.
I'm holding and adding.
Work it out for yourselves. Edison is a starter. Just do a chronological review re sareum and Edison.
Going to make pancakes now.

Ndr let me get back to you re 737 . You can research it yourself. Go back 4/5 years when you research. The devil is in the detail

Blastoid. Hi.
Just for a bit of fun....absolute respect your posts but I believe we have been hoodwinked.
Look up Edison group. com.18th September 2017.
Liked us...went silent...then started reporting again last year. And we got investors!
In it to win it. The consolidation discussion re PH are a smoke screen.

Here you go 3rd January 2019 ...not great at cut and paste....strap in..

They pointed out that includes Bristol-Myers Squibb’s TYK2 (Tyrosine Kinase 2) protein-coding gene candidate, an inhibitor which is used as a treatment for autoimmune conditions.

The analysts noted that they have previously mused that the inhibitive qualities of Sareum’s two candidates in the same space could mean that, along with other qualities, its assets could emerge as best in class.

They said their review of the clinical evidence so far suggests that Sareum’s JAK1 (Janus kinase) inhibitor – which is one of the same family as TYK2 - could provide some additional efficacy particularly in autoimmune conditions such as Psoriasis.

The analysts concluded that even with today’s share price jump – up 19% to 0.62p in late afternoon trading -- Sareum’s market cap of just £18mln makes the firm “arguably a bargain target for the relatively large group of Biotech and Pharma companies interested in TYK2 and the wider JAK inhibitor space.”
Regards Steadydanny

https://www.proactiveinvestors.co.uk/LON:SAR/Sareum-Holdings-Plc/
This has been known about. Not sure if the link will work but June 2019. Proactive investors! Read it.
Then recall the squeaky chair q and a ...$320 billion market potential!!! And this...

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation (“CTA”) have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

Imo I'm buying more and did today. PH have had the opportunity to report this. They haven't! Why not?
Because they have been losing money since their listing!
Hold the line.

Cobalt your response to my concern over PH

I've long given up on trying to understand the disjointed rambling of SD.

Just block me. Job done .
Then just listen to what you want to.
For a bb with a company at around £160m there is comparatively a significant amount of conversation here. People who believe in the science . Albeit since PH arrived we have nosedived! Who are supposed to be a positive appointment.
What do we get
SILENCE!
Is that value for money?
We have been advised the tox results are positive but no follow up. They could release something prior to full release otherwise ongoing trials would have been stalled.
We are being manipulated.

Quote is after the word technology.
Sorry for late reply...watching Constant Gardener.
Worth a watch.

This from December last year and peel hunt listing

Peel Hunt has seen its earnings more than halve following a rise in costs related to its initial public offering and investment in technology.
The board need to get rid of PH ASAP!
We need an EGM pronto.
Please all investors email the board ASAP.
They are probably hoping that we as shareholders turn the tables on PH. As in somehow they are beholden and can't respond.
Peel Hunt OUT OUT OUT
Let them feckin burn in hell as they have caused misery elsewhere. Not just here.
Look up the names of their employees and their links to certain government individuals. And big banks.

Cobalt please explain why you say yawn.

Dr Steve James called him out. As did the nurses silence. You can look it up.its fact. I sincerely think the extensions and late delivery of toxicology results are that they are trying to dismiss us.
Wtaf has ph done here in a positive context as a Joint broker? Hybridan gone quiet.
I'm so ready for a Norwich Pharmacal Order !
Trust me it protects your investment. They will **** their pants. 3rd parties wanting to lose their companies!?

From JP Morgan. Last year.

London, June 26, 2021 – Sajid Javid has left his role as a member of J.P. Morgan’s EMEA Advisory Council following his appointment to the U.K. government today as Secretary of State for Health and Social Care. Mr. Javid had been a member of the Council since August 2020.

Founded in 2005, J.P. Morgan's EMEA Advisory Council comprises of a distinguished group of senior advisors from both the public and private sectors who provide the bank and its clients with insight into local market opportunities and wider macro issues.

Vittorio Grilli, Chairman of the Council, said: “Sajid’s experience across business and public life has provided a vital broader perspective that both the J.P. Morgan team and our clients are grateful to have benefited from. It is important for all companies to have the wisdom of trusted advisors who are away from the day-to-day of running the business to consider how to invest for the future.”

Vis Raghavan, CEO of EMEA at J.P. Morgan, added: “I’d like to thank Sajid for the time he has spent with J.P. Morgan. We all wish him the very best as he takes on such an important role as Health Secretary, and at what is a crucial time for our country as we look to recover from the pandemic.”

Any one else think his position is untenable?

Sierra Oncology to Present at HC Wainwright BioConnect Conference

01/05/2022

SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 7:00 am ET on Monday, January 10 to conference attendees.

A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab. The replay will be available for approximately 90 days following the presentation.

About Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.

Sincerely wish some good news for investors here and I think imo 737 has a bit more to it than has been released. Note they state late stage!
Some cracking posters here who keep the research and potential in the limelight. And just to say Ahfam last year came across the il-6 potential. Once again best regards to you Ahfam and your family and just want to say I enjoy and respect your posts.
Very best regards Steadydanny

Hi Afham. So sorry to hear of your fathers passing. Thoughts and prayers to you and your family.

Very interesting post Citizen re dementia and Alzheimer's. We had stories locally that broke early 2020 in such specialist care homes that got buried.
Not going into details but you can look up Brandon House Exmouth.

Fuel not few!

Hi WIP. I have decided that family members and friends who just undertake the msm protocol are actually a concern. They have no ability to critically think. Albeit when **** hits the fan they ask my advise. I pointed out maslows triangle back along. Look at few prices!
Done and dusted with them. Quite refreshing actually.
Best regards to you. Appreciate you see the picture.

WIP all I ask for is whitty and van tam and fauci to do a live open debate with Malone and the Kennedy chap et al.
Surely that should be reasonable to answer those who have different opinions.
Surely then it would be a closed debate re vaccines. But they don't allow it. Individuals need to look up malone. He is not a one trick pony.

Del please tell me how a consolidation can take place when research bought and paid for by investors can go forward when initial toxicology results show promise and the board give go ahead for CTA!?
There is no way in a month of Sundays that a consolidation can take place with results pending from shareholders funds that are released post a possible consolidation. That would be criminal!!!
Seriously wtf is going on here?
This is getting ridiculous!